亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.

医学 内科学 实体瘤疗效评价标准 癌症 肿瘤科 中性粒细胞减少症 宫颈癌 肺癌 胃肠病学 毒性 临床研究阶段
作者
Jordi Rodón,Cesar A. Perez,Kit Man Wong,Michael L. Maitland,Frank Tsai,Jordan Berlin,Ken Liao,I‐Ming Wang,Lada Markovtsova,Ira Jacobs,Nora Cavazos,Meng Li,Anthony W. Tolcher
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 3019-3019 被引量:32
标识
DOI:10.1200/jco.2021.39.15_suppl.3019
摘要

3019 Background: Protein arginine methyltransferase 5 (PRMT5) methylates multiple substrates known to be dysregulated in cancer, including components of the spliceosome machinery. PF-06939999 is a selective small-molecule inhibitor of PRMT5. Here we report the safety, PK, PD, and preliminary activity of PF-06939999 in patients (pts) with selected advanced/metastatic solid tumors. Methods: This phase 1 dose escalation trial (NCT03854227) enrolled pts with solid tumor types marked by potential frequent splicing factor mutations, including advanced/metastatic endometrial cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), urothelial cancer, cervical cancer, or esophageal cancer. PF-06939999 monotherapy was continuously administered orally QD or BID in 28-day cycles. A Bayesian Logistic Regression Model was used to inform dose level decisions. Primary objectives were to assess dose limiting toxicities (DLTs), AEs and laboratory abnormalities. Tumor response was assessed using RECIST v1.1. PK and PD were assessed by determining PF-06939999 plasma concentration after dosing and changes in plasma levels of symmetric di-methyl arginine (SDMA), the product of PRMT5 enzymatic activity. Results: 28 pts received PF-06939999 at doses from 0.5-12 mg daily (QD or BID) during dose escalation. Median number of cycles was 2 (range, 1-13). Most were female (54%) with a median age of 61.5 (range, 32-84) y. Median number of prior therapies was 4. Overall, 4/24 (17%) pts reported DLTs: thrombocytopenia (n=2, 6 mg BID); anemia (n=1, 8 mg QD); and neutropenia (n=1, 6 mg QD). Treatment-related AEs occurred in 24 (86%) pts. Most common (≥20%) treatment-related AEs across all cycles were anemia (43%), thrombocytopenia (32%), dysgeusia, fatigue and nausea (29% each). Grade ≥3 treatment-related AEs included anemia (25%), thrombocytopenia (21%), fatigue, neutropenia and lymphocyte count decreased (4% each). One pt (6mg BID) had Grade 4 treatment-related thrombocytopenia. All cytopenias were dose-dependent and reversible with dose modification. No pts discontinued treatment for treatment-related toxicity. There were no treatment-related deaths. Exposure to PF-06939999 increased with doses in the dose range tested. Plasma SDMA was reduced at steady state (58.4-87.5%), indicating robust PD target inhibition. Two pts had confirmed partial response (HNSCC and NSCLC). 6 mg QD was identified as the recommended monotherapy dose for expansion. Conclusions: PF-06939999 showed dose-dependent and manageable toxicities in this phase 1 dose escalation study. Objective tumor responses were observed in pts with HNSCC and NSCLC. Analysis of archival tissue for the presence of splicing factor mutations and other potential predictive biomarkers is ongoing. Enrollment to part 2 dose expansion is ongoing in pts with NSCLC, HNSCC and urothelial cancer. Clinical trial information: NCT03854227.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
完美世界应助nsc采纳,获得10
10秒前
量子星尘发布了新的文献求助10
26秒前
所所应助nsc采纳,获得10
34秒前
小蘑菇应助nsc采纳,获得50
34秒前
Ava应助nsc采纳,获得10
34秒前
隐形曼青应助nsc采纳,获得10
34秒前
慕青应助nsc采纳,获得10
34秒前
脑洞疼应助nsc采纳,获得10
34秒前
善学以致用应助nsc采纳,获得10
34秒前
ding应助nsc采纳,获得30
34秒前
Hello应助nsc采纳,获得10
34秒前
烟花应助nsc采纳,获得10
34秒前
41秒前
42秒前
漫步随心完成签到,获得积分20
1分钟前
NexusExplorer应助科研通管家采纳,获得10
1分钟前
1分钟前
今后应助nsc采纳,获得10
1分钟前
bkagyin应助nsc采纳,获得10
1分钟前
小二郎应助nsc采纳,获得10
1分钟前
Jasper应助nsc采纳,获得10
1分钟前
李爱国应助nsc采纳,获得10
1分钟前
脑洞疼应助nsc采纳,获得10
1分钟前
慕青应助nsc采纳,获得10
1分钟前
天天快乐应助nsc采纳,获得10
1分钟前
Akim应助nsc采纳,获得10
1分钟前
充电宝应助nsc采纳,获得10
1分钟前
量子星尘发布了新的文献求助30
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3957061
求助须知:如何正确求助?哪些是违规求助? 3503084
关于积分的说明 11111255
捐赠科研通 3234121
什么是DOI,文献DOI怎么找? 1787751
邀请新用户注册赠送积分活动 870762
科研通“疑难数据库(出版商)”最低求助积分说明 802264